Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, February 10, 2023

Butylphthalide improved outcomes in more than half of patients with ischemic stroke

This from December 2021 should have initiated more human research, but since we have NO stroke leadership and NO stroke strategy we still have nothing useful that will help survivors.

Butylphthalide Combined With Conventional Treatment Attenuates MMP-9 Levels and Increases VEGF Levels in Patients With Stroke: A Prospective Cohort Study

 December 2021

 The latest here,which will accomplish nothing. Our stroke medical world is completely fucking incompetent!

Butylphthalide improved outcomes in more than half of patients with ischemic stroke

Butylphthalide improved 90-day clinical outcomes in those with acute ischemic stroke who also received IV recombinant tissue plasminogen activator and/or endovascular treatment, per research presented at International Stroke Conference.

“The medication was given to patients with acute ischemic stroke who were also receiving treatment to restore blood flow to the brain,” Baixue Jia, MD, co-author of the study and physician in interventional neuroradiology at Beijing Tiantan Hospital of Capital Medical University, stated in a related press release.

Older man having stroke
A recent study found that patients who received butylphthalide along with clot treatment for ischemic stroke had better functional outcomes after 90 days. Source: Adobe Stock

Jia and colleagues sought to evaluate the efficacy of butylphthalide for improving functional outcomes in those with acute ischemic stroke who previously received IV recombinant tissue plasminogen activator and/or endovascular treatment.

They conducted a double-blind, placebo-controlled trial and included 1,216 individuals (median age, 66 years; 68% men) across 59 centers who were randomized on a 1:1 basis to receive IV butylphthalide (n = 607) or placebo (n = 609) for 14 days, followed by 76 days of oral capsules.

The primary outcome of interest was adjusted favorable outcome at 90 days, defined by scores on three metrics: 0 on the modified Rankin Scale (mRS) in patients with a baseline score of 4 to 7 on the NIH Stroke Scale (NIHSS), an mRS score of 0 to 1 in patients with a baseline NIHSS score of 8 to 14 and an mRS score of 0 to 2 in patients with a baseline NIHSS score of 15 to 25. Secondary outcomes included symptomatic intracranial hemorrhage, stroke recurrence and death.

Analysis was performed in the intention-to-treat population and in subcategories based on age, sex, baseline NIHSS score, hypertension and method of reperfusion.

Researchers reported a favorable outcome on day 90 in 344 participants (56.7%) treated with butylphthalide and 268 individuals (44%) in the placebo group (OR = 1.7; 95% CI, 1.35-2.14), with similar secondary outcomes between cohorts.

“This is the first trial to show the benefit of using a medication that protects the brain from damage caused by a lack of oxygen to brain tissue,” Jia said in the release. “If the results are confirmed in other trials, this may lead to more options to treat strokes caused by clots.”

Reference:

Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)